GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Net Margin %

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Net Margin % : 21.95% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Laboratorios Farmaceuticos Rovi's Net Income for the three months ended in Dec. 2023 was €51.5 Mil. Laboratorios Farmaceuticos Rovi's Revenue for the three months ended in Dec. 2023 was €234.6 Mil. Therefore, Laboratorios Farmaceuticos Rovi's net margin for the quarter that ended in Dec. 2023 was 21.95%.

The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Net Margin % or its related term are showing as below:

XMAD:ROVI' s Net Margin % Range Over the Past 10 Years
Min: 5.9   Med: 10.22   Max: 24.42
Current: 17.69


XMAD:ROVI's Net Margin % is ranked better than
88.74% of 1030 companies
in the Biotechnology industry
Industry Median: -154.79 vs XMAD:ROVI: 17.69

Laboratorios Farmaceuticos Rovi Net Margin % Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Net Margin % Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.30 14.54 23.60 24.42 20.53

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.54 10.71 24.38 21.95 9.90

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Net Margin %

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Net Margin % distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Net Margin % falls into.



Laboratorios Farmaceuticos Rovi Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Laboratorios Farmaceuticos Rovi's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=170.335/829.509
=20.53 %

Laboratorios Farmaceuticos Rovi's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=51.508/234.636
=21.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Laboratorios Farmaceuticos Rovi Net Margin % Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 01-05-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 529,463 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

TiVo Corporation to Announce First Quarter 2020 Results

By Business Wire Business Wire 04-23-2020

ITC Reaffirms TiVo's Second Infringement Victory

By Business Wire Business Wire 04-23-2020

Pluto TV Partners With TiVo to Expand the TiVo+ Content Network

By Business Wire Business Wire 05-05-2020

Rovi Corp. (ROVI) EVP & CFO James Budge sells 44,145 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011